[{"id":"c40fa03c-9c20-4928-9562-c4d2f144ca96","acronym":"DAR-UM-2","url":"https://clinicaltrials.gov/study/NCT05987332","created_at":"2023-08-14T15:10:06.767Z","updated_at":"2025-02-25T16:27:34.251Z","phase":"Phase 2/3","brief_title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","source_id_and_acronym":"NCT05987332 - DAR-UM-2","lead_sponsor":"IDEAYA Biosciences","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)"],"overall_status":"Recruiting","enrollment":" Enrollment 420","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 01/15/2028","study_completion_date":" 01/15/2028","last_update_posted":"2025-02-04"},{"id":"a3420852-8b9f-44e2-8ed6-3f7ccc1cb129","acronym":"BASECAMP-1","url":"https://clinicaltrials.gov/study/NCT04981119","created_at":"2021-07-28T19:52:39.410Z","updated_at":"2025-02-25T17:37:14.992Z","phase":"","brief_title":"Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","source_id_and_acronym":"NCT04981119 - BASECAMP-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-29"},{"id":"a1bfec25-d893-4cf6-93c8-c3f71ddf2444","acronym":"DURANCE","url":"https://clinicaltrials.gov/study/NCT04106115","created_at":"2021-01-18T20:04:52.084Z","updated_at":"2025-02-25T15:08:49.394Z","phase":"Phase 1/2","brief_title":"DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr","source_id_and_acronym":"NCT04106115 - DURANCE","lead_sponsor":"University College, London","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • S-588210"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/25/2022","start_date":" 03/25/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-12-04"},{"id":"45804b31-abb5-4caf-bfa4-174bafa136c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535078","created_at":"2021-01-18T12:15:32.419Z","updated_at":"2025-02-25T15:06:47.576Z","phase":"Phase 1/2","brief_title":"Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma","source_id_and_acronym":"NCT02535078","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • HLA-A*02:01 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 06/19/2023","primary_completion_date":" 06/19/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-24"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"7f32c6ae-db00-48e3-960e-6cced44274a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05973487","created_at":"2023-08-03T15:09:34.671Z","updated_at":"2024-07-02T16:34:25.733Z","phase":"Phase 1","brief_title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","source_id_and_acronym":"NCT05973487","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A • PRAME • HLA-C","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-06-14"},{"id":"189c84d8-9170-41ee-88a7-ba2d750c2705","acronym":"PRISM-MEL-301","url":"https://clinicaltrials.gov/study/NCT06112314","created_at":"2023-11-01T15:12:45.028Z","updated_at":"2024-07-02T16:34:26.248Z","phase":"Phase 3","brief_title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","source_id_and_acronym":"NCT06112314 - PRISM-MEL-301","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"74c31265-1520-4843-8d42-dcf55e82cdf5","acronym":"TSCAN-001","url":"https://clinicaltrials.gov/study/NCT05473910","created_at":"2022-07-26T17:09:59.782Z","updated_at":"2024-07-02T16:34:26.524Z","phase":"Phase 1","brief_title":"A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation","source_id_and_acronym":"NCT05473910 - TSCAN-001","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • HLA-A positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • TSC-100 • TSC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"8219a865-ee1b-4147-b478-9542d52eab59","acronym":"","url":"https://clinicaltrials.gov/study/NCT02858310","created_at":"2021-01-18T14:01:47.880Z","updated_at":"2024-07-02T16:34:58.731Z","phase":"Phase 1/2","brief_title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","source_id_and_acronym":"NCT02858310","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/27/2017","start_date":" 01/27/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-06-05"},{"id":"3459cfe0-8df3-41ce-b99a-ba11d3ea3232","acronym":"EVEREST-2","url":"https://clinicaltrials.gov/study/NCT06051695","created_at":"2023-09-25T14:10:18.366Z","updated_at":"2024-07-02T16:34:59.359Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT06051695 - EVEREST-2","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-06-04"},{"id":"897414a3-bc36-4d90-b0c6-902256e6b2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334865","created_at":"2021-02-24T21:53:04.763Z","updated_at":"2025-02-25T14:35:10.773Z","phase":"Phase 1","brief_title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","source_id_and_acronym":"NCT02334865","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2024-06-04"},{"id":"89a914ac-06d5-4cf1-bba9-6ccd8e3df332","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083883","created_at":"2023-10-16T16:13:47.307Z","updated_at":"2024-07-02T16:34:59.004Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1","source_id_and_acronym":"NCT06083883","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B • SSX1","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • CTAG1B • SSX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/27/2024","start_date":" 03/27/2024","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2024-06-04"},{"id":"8af52e0c-a6ec-4403-a6fa-b9543bc969cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066359","created_at":"2023-10-04T15:10:43.929Z","updated_at":"2024-07-02T16:34:59.118Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT06066359","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/30/2023","start_date":" 11/30/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-06-04"},{"id":"9bdad34e-56d0-48b9-af40-2c4c90d60427","acronym":"WP42004","url":"https://clinicaltrials.gov/study/NCT04580121","created_at":"2021-06-30T14:53:56.262Z","updated_at":"2024-07-02T16:34:59.484Z","phase":"Phase 1","brief_title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","source_id_and_acronym":"NCT04580121 - WP42004","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/04/2020","start_date":" 11/04/2020","primary_txt":" Primary completion: 08/09/2023","primary_completion_date":" 08/09/2023","study_txt":" Completion: 08/09/2023","study_completion_date":" 08/09/2023","last_update_posted":"2024-06-03"},{"id":"2b7c4292-573a-4f4f-aeb9-0287544f452d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592888","created_at":"2021-01-18T17:39:37.238Z","updated_at":"2024-07-02T16:35:05.451Z","phase":"Phase 1","brief_title":"DC Vaccine in Pancreatic Cancer","source_id_and_acronym":"NCT03592888","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS • HLA-A","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11","tags":["KRAS • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/20/2018","start_date":" 11/20/2018","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-05-07"},{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"345523f2-eb95-47c4-aa63-da74c79fb6fc","acronym":"EVEREST-1","url":"https://clinicaltrials.gov/study/NCT05736731","created_at":"2023-02-21T15:01:17.869Z","updated_at":"2024-07-02T16:35:10.811Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT05736731 - EVEREST-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • HLA-A*02","tags":["HLA-A • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e A2B530"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-04-09"},{"id":"68a67f53-3f78-4080-af42-75466b7cacd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04262466","created_at":"2021-01-18T20:42:48.114Z","updated_at":"2024-07-02T16:35:12.070Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","source_id_and_acronym":"NCT04262466","lead_sponsor":"Immunocore Ltd","biomarkers":" HLA-A • PRAME","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Kimmtrak (tebentafusp-tebn) • brenetafusp (IMC-F106C)"],"overall_status":"Recruiting","enrollment":" Enrollment 727","initiation":"Initiation: 02/25/2020","start_date":" 02/25/2020","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-02"},{"id":"7fc864bc-2037-4926-9819-2552b751ef5d","acronym":"ATTAC-MCC","url":"https://clinicaltrials.gov/study/NCT03747484","created_at":"2021-06-30T14:53:31.876Z","updated_at":"2024-07-02T16:35:12.716Z","phase":"Phase 1/2","brief_title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","source_id_and_acronym":"NCT03747484 - ATTAC-MCC","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2025","study_completion_date":" 01/10/2025","last_update_posted":"2024-03-26"},{"id":"ec343796-9a7d-4a37-ae58-20833927f291","acronym":"","url":"https://clinicaltrials.gov/study/NCT05867056","created_at":"2023-05-19T13:04:58.836Z","updated_at":"2024-07-02T16:35:13.966Z","phase":"Phase 1","brief_title":"Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection","source_id_and_acronym":"NCT05867056","lead_sponsor":"Immunocore Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 09/10/2024","primary_completion_date":" 09/10/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-03-19"},{"id":"4f0f45d6-2518-42e6-9e5e-59562321231d","acronym":"TEBE-AM","url":"https://clinicaltrials.gov/study/NCT05549297","created_at":"2022-09-22T15:56:24.575Z","updated_at":"2024-07-02T16:35:15.907Z","phase":"Phase 2/3","brief_title":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","source_id_and_acronym":"NCT05549297 - TEBE-AM","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kimmtrak (tebentafusp-tebn)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-03-07"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"fc2b490f-716a-4fb8-8ba2-7e656cf95939","acronym":"SURPASS","url":"https://clinicaltrials.gov/study/NCT04044859","created_at":"2021-01-18T19:50:41.997Z","updated_at":"2024-07-02T16:35:19.014Z","phase":"Phase 1","brief_title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","source_id_and_acronym":"NCT04044859 - SURPASS","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 04/30/2037","study_completion_date":" 04/30/2037","last_update_posted":"2024-02-16"}]